Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. EOLS

(EOLS)

NGM – Real Time Price. Currency in USD

4.01

-0.16 (-3.84%)

At close: Mar 27, 2026, 4:00 PM EDT

4.06

+0.05 (1.25%)

After-hours: Mar 27, 2026, 7:59 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
4.01$
Day's range
3.98 - 4.17$
52-week range
3.98 - 12.51$
Volume
955 464
Average volume
1 037 478
Beta
0.27
EPS (TTM)
-0.8
PE ratio (TTM)
N/A
Market cap
260 890 575
Shares outstanding
65 059 994
Dividend yield
N/A
Next earnings date
2026-05-12
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

About the company

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various produc... read more
CEO
David Moatazedi
Country
United States
IPO Date
2018-02-08
Employees
334
Fiscal Year End
January - December
Website
https://www.evolus.com

Revenue Breakdown

Medical Aesthetics / 100.00%

News

No Data

There are no news for this stock.

Chart: EOLS

Loading Chart...

Overall Score

3.9 / 1039%
Financial Strength
4.4
Profitability
4.4
Effectiveness
1
Growth
7.9
Forecast
8.8
Valuation
2.4

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio1.902.529.0
Quick ratio1.541.788.0
Debt to EquityN/A-0.801.0
Debt to Assets0.690.733.0
Interest coverage-0.07-13.901.0
Weighted average score4.4

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2022202320242025TTM
Total Revenue149M202M266M297M297M
Gross Profit89M135M180M193M193M
Operating Income-60M-36M-27M-38M-38M
Net Income-74M-62M-50M-52M-52M
EBITDA-55M-30M-21M-29M-29M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %64.0649.73
10
Operating margin %-0.320.39
1.0
Net margin %0.14-50.32
2.0
EBITDA margin %2.55-16.02
2.0
Cash flow margin %14.20124.71
7.0
Weighted average score4.4

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA-25.25-42.45
1.0
ROEN/A-63.95
1.0
ROIC-42.87-2.18
1.0
ROCE-5.9342.71
1.0
Weighted average score1.0

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarter5.4925.787.5
Next quarter18.384.269.5
Current year11.0565.468.5
Next year17.62236.269.5
Weighted average score8.8

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q30.93100.83133.45172.6310
Y/Y14.38101.9135.09159.689.5
3y average26.4510.986.78-10.345.8
5y average40.959.0514.33-28.946.3
Weighted average score7.9

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/EN/A13.57
1.0
PEG (5yr expected)N/A0.41
1.0
P/S1.01-0.30
6.0
P/B53.716.01
1.6
Weighted average score2.4

DCF Model

DCF Model PeriodN/A
Discount rateN/A
Perpetual growth rateN/A
Revenue 5 year CAGRN/A
FCF 5 year CAGRN/A
Fair value$
Stock price4.01$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$1

UndervaluedStock priceOvervalued

$4.01

Economic Moat

NAMESCALESCORE
Market shareNone1.0
Intangible assetsNone1.0
Switching costsNone1.0
Network effectNone1.0
Economies of scaleNone1.0
Weighted average score1.0
Dividend
1
Economic Moat
1

Octagon View

Strength & Weakness

Total debt $155.0M significantly exceeds cash reserves ($53.8M), raising financial stability concerns

Total current assets $142.9M exceed Total current liabilities $75.3M, highlighting excellent liquidity

Debt-to-equity ratio (-6.7) is well below the industry average (-0.8), showcasing prudent financial management

Interest coverage ratio (-0.1x) is dangerously low, suggesting debt repayment risks

The company generates positive free cash flow $11.3M, supporting its financial health